Mitchell Brin, MD, FAAN
Dr. Mitchell Brin is a physician neurologist with extensive patient care and clinical development experience with 28 years of pharmacology, experimental therapeutics, small molecule and neurotoxin (including Oculinum® / BOTOX® / Myobloc® / Dysport®) research on a background of extensive patient care.
This research & development experience includes 17 years academic experimental therapeutic (drug/biologics/device) and genetic clinical trials with studies supported by competitive U.S. Food and Drug Administration grants and awards, the National Institutes of Health, private philanthropy and 11 years in the biopharmaceutical industry.
Dr. Brin graduated with a Bachelor of Arts degree in Biology from the University of Pennsylvania (Magna Cum Laude, Phi Beta Kappa) and received his Medical Degree from Columbia College of Physicians and Surgeons.
He completed a medical internship at the Mount Sinai Medical Center, neurology training at the Columbia University Neurological Institute, followed by a fellowship in Movement Disorders at the Neurological Institute, where he became an Assistant Professor and Coordinator of the Dystonia Clinical Research Center.
In 1994, Dr. Brin joined the staff at Mount Sinai School of Medicine, subsequently received the Bachmann-Strauss Endowed Chair in Neurology and was promoted to Professor.
In 2001, Dr. Brin joined Allergan as Vice President of Development, and Therapeutic Area Head for BOTOX® & Neurology. Subsequently promoted to Senior Vice President, he was responsible for the Global Registration Development program for therapeutic and aesthetic biologics and neurology small molecules.
In 2007, he assumed the responsibilities of Senior Vice President Global Drug Development, and Chief Scientific Officer for BOTOX®. In this capacity, he provides strategic cross-functional support of the neurotoxin and next generation biologics program.
This includes global scientific support and clinical expertise across the continuum of all BOTOX® therapy (cosmetic and therapeutic) product research, development, regulatory, drug safety, safety pharmacology, formulation, medical affairs and corporate strategy. He continues to publish actively and is a Professor of Neurology at the University of California Irvine, where he evaluates and treats patients.